Biotechnology stocks are hot. New developments in clinical trials and drug approvals have become commonplace. And buyouts of biotech stocks at high premiums are increasing. Here is how to get your share of the outsized gains that are being generated. Let’s explore the issue with the help of two charts.Read More →
© Reuters. FILE PHOTO: Switzerland’s national flag flies in front of the logo of Swiss drugmaker Novartis in Basel (Reuters) – Swiss drugmaker Novartis AG (S:) is nearing an agreement to acquire U.S. biotechnology firm The Medicines Co (O:) for about $7 billion, the Wall Street Journal reported on Saturday.Read More →
Catey Hill helps MarketWatch readers find retirement destinations that fit their specific wish lists. Most are looking for cheaper places to live. But now a reader with a net worth of $5 million wants someplace that isn’t stiflingly hot, has good health care and isn’t in California. She offered threeRead More →
To be a successful investor, you must always remember that there are many people in the stock market who are much smarter than you are. That brings two benefits. It helps you avoid arrogance, which the market invariably punishes, often severely. And it reminds you there are plenty of portfoliosRead More →
Gossamer Bio, Inc., a company with six drugs in its pipeline, is planning to go public and has applied to list on the Nasdaq exchange under the ticker symbol “GOSS.” Three of the company’s drugs are in clinical trials, while the rest are still in preclinical stages of development. TheRead More →
